Product Pipeline: ONC-781

A major advance in immunotherapy is to targeting T cell to cancer cells through either bi-specific antibodies or chimeric antigen receptors for T cells (CAR-T).  While this approach has been transformative for some hematological malignancies, its impact on solid tumors has been very limited, in part due to the lack of appropriate target and targeting agents that are specific for cancer cells.  Our ONC-781 program is based on a novel antigenic glyco-epitope that is broadly expressed on cancer tissues but essentially absent in normal tissues. We have developed a novel monoclonal antibody ONC-781 that binds to this novel glycoform and demonstrated differential binding to cancer tissues but not normal tissues.

Subsequently, we have developed bispecific antibodies and CAR-T cells using this novel antibody that show broad reactivity to hepatocellular carcinoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, prostate cancer, lung cancer and essentially all types of malignant brain tumors.  Our systemic characterization of the proprietary target reveal that the epitope is encoded by a gene that is over-expressed and fundamentally important for cancer cell growth and metastasis.  It is shielded in normal cells by a specific glycosylation.   Since the antigenic epitope is on an oncogene that is critical for cancer growth and metastasis, it is anticipated that cancer cells would be hard-pressed to lose the antigen to evade ONC-781-based immunotherapy.

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.